; (C) a premarket application under section 587B of the Federal Food, Drug, and Cosmetic Act, as added by section 3, or technology certification application under section 587D of such Act, as added by section 3, is submitted no later than— (i) 5 years after the effective date of this Act, if the in vitro clinical test is approved by the New York State Department of Health as a genetic testing molecular test, a microbiology molecular test, an oncology molecular test, or any other type of molecular test; or (ii) 2 years after the effective date of this Act, if the in vitro clinical test is approved by the New York State Department of Health as a type of test not described in clause (i); and (D) a test in compliance with this paragraph may continue to be offered, sold, or distributed, as applicable, until the completion of the Secretary’s review of the premarket application or technology certification application described in subparagraph (C). (d) Conversion (1) Deemed premarket approval Beginning on the effective date of this Act— (A) any in vitro clinical test with a premarket approval under section 515 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360e ) or a licensure under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ) is deemed to be approved pursuant to an application under section 587B(a) of the Federal Food, Drug, and Cosmetic Act, as added by this Act